$HALB Halberd (HALB) Pursuing a Nasal Spray to Cou
Post# of 630
(Total Views: 224)
Posted On: 05/02/2023 8:21:01 AM
$HALB Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
https://www.accesswire.com/752367/Halberd-HAL...ead-Trauma
Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process
JACKSON CENTER, PA / ACCESSWIRE / May 2, 2023 / Halberd Corporation (OTC PINK:HALB) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of this study by Halberd and Mississippi State University is to discover the effectiveness of the nasal spray against multiple antigens, linked to head trauma and various neurodegenerative conditions like PTSD, Alzheimer's Disease, early onset Alzheimer's Disease, and Epilepsy.
Medical literature indicates that a pathophysiologic connection exists between various excess neurotransmitters and certain neurodegenerative diseases. Halberd's study aims to establish positive outcomes through limiting the presence of excess neurotransmitters through its nasal spray work at Mississippi State University College of Veterinary Medicine, led by Dr. Russell Carr.
This nasal spray technology represents an expansion of Halberd's extracorporeal methodology in treating medical conditions through a preventative approach and provides an additional avenue for developing research contracts/grants and future revenue streams. Understanding the mechanism of action of a nasal spray on various constituents in the brain will help further define and enhance Halberd's extracorporeal targeting and eradication of specific diseases and conditions.
The goal of the study is to be concluded within six months.
https://www.accesswire.com/752367/Halberd-HAL...ead-Trauma
Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process
JACKSON CENTER, PA / ACCESSWIRE / May 2, 2023 / Halberd Corporation (OTC PINK:HALB) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray. The nasal spray is designed to counteract the generation of excess inflammatory cytokines resulting from head trauma. The focus of this study by Halberd and Mississippi State University is to discover the effectiveness of the nasal spray against multiple antigens, linked to head trauma and various neurodegenerative conditions like PTSD, Alzheimer's Disease, early onset Alzheimer's Disease, and Epilepsy.
Medical literature indicates that a pathophysiologic connection exists between various excess neurotransmitters and certain neurodegenerative diseases. Halberd's study aims to establish positive outcomes through limiting the presence of excess neurotransmitters through its nasal spray work at Mississippi State University College of Veterinary Medicine, led by Dr. Russell Carr.
This nasal spray technology represents an expansion of Halberd's extracorporeal methodology in treating medical conditions through a preventative approach and provides an additional avenue for developing research contracts/grants and future revenue streams. Understanding the mechanism of action of a nasal spray on various constituents in the brain will help further define and enhance Halberd's extracorporeal targeting and eradication of specific diseases and conditions.
The goal of the study is to be concluded within six months.
(0)
(0)